News
An updated guideline on pharmacotherapy of obesity management in adults includes six new and seven revised recommendations, ...
Patients with psoriasis have significantly more difficulty sleeping, particularly in new environments, than matched ...
10hon MSN
Shares of Eli Lilly (NYSE: LLY), the pharmaceuticals giant and maker of the Mounjaro and Zepbound weight loss drugs, saw its ...
Leaders at Eli Lilly believe heavy investment in the company's manufacturing footprint “sets a high standard that newcomers ...
The up to $100 million in state tax incentives for a $3 billion Eli Lilly expansion in Kenosha County isn’t the only tax ...
This will be the first time the option has been taken up since it was introduced at the beginning of 2025, under the Medical ...
Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...
Eli Lilly and Company (NYSE: LLY) is one of the Good Stocks to Invest in Now. On August 7, Eli Lilly and Company (NYSE:LLY) ...
In a phase 3 trial, the daily GLP-1 pill has shown "meaningful weight loss" and similar side effects to injectable GLP-1 drugs like Ozempic, Eli Lilly has said., Health, Times Now ...
Eli Lilly and Company (NYSE: LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded ...
22h
Fashion Glamp on MSNA Pivotal Advance in Obesity Treatment: Eli Lilly's Oral Pill Shows Significant Weight Loss in Landmark TrialA transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...
Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results